{"id":709122,"date":"2024-08-07T16:24:01","date_gmt":"2024-08-07T16:24:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=709122"},"modified":"2024-08-07T16:24:01","modified_gmt":"2024-08-07T16:24:01","slug":"the-biopharmaceutical-excipients-market-to-reach-379-billion-by-2029-merck-kgaa-basf-se-avantor-evonik-industries-ag-are-the-major-stakeholders-arizton","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/the-biopharmaceutical-excipients-market-to-reach-379-billion-by-2029-merck-kgaa-basf-se-avantor-evonik-industries-ag-are-the-major-stakeholders-arizton_709122.html","title":{"rendered":"The Biopharmaceutical Excipients Market to Reach $3.79 Billion by 2029, Merck KGaA, BASF SE, Avantor, & Evonik Industries AG are the Major Stakeholders – Arizton"},"content":{"rendered":"
\n
\"The<\/a><\/div>\n
\n
Global Biopharmaceutical Excipients Market – Focused Insights 2024-2029<\/div>\n<\/div>\n<\/div>\n

 <\/p>\n

According to Arizton’s latest research report, the global biopharmaceutical excipients market<\/a> is growing at a CAGR of 7.67% during 2023-2029. <\/p>\n

\u202f\u202f <\/p>\n

Curious to Know More About the Market? Click: https:\/\/www.arizton.com\/market-reports\/biopharmaceutical-excipients-market<\/a> <\/strong><\/p>\n

 <\/p>\n

Report Scope\u202f\u202f\u202f\u202f\u202f\u202f <\/strong><\/p>\n

Market Size (2029):<\/strong> $3.79 Billion\u202f\u202f\u202f\u202f\u202f <\/p>\n

Market Size (2023):<\/strong> $2.43 Billion\u202f\u202f\u202f\u202f\u202f <\/p>\n

CAGR (2023-2029):<\/strong> 7.67%\u202f\u202f\u202f\u202f\u202f\u202f <\/p>\n

Historic Year:\u202f<\/strong> 2020-2022\u202f\u202f\u202f\u202f\u202f <\/p>\n

Base Year:<\/strong> 2023\u202f\u202f\u202f\u202f\u202f <\/p>\n

Forecast Year:<\/strong> 2024-2029\u202f\u202f\u202f\u202f\u202f <\/p>\n

Market Segmentation:<\/strong> Excipient, Biologics, Scale of Operations, Origin, End-Users, and Geography <\/p>\n

\u202f\u202f\u202f <\/p>\n

Stay ahead of the curve with Arizton’s exclusive subscription plan, offering in-depth analysis, market sizing, and growth forecasts for less than $900 per month—a significant value compared to individual report purchases. Click here: https:\/\/www.arizton.com\/subscription<\/a>\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f <\/strong><\/p>\n

 <\/p>\n

The increasing demand for biopharmaceuticals is significantly driving the need for excipients in the production of biological drugs. As cancer and infectious diseases become more prevalent, there is a heightened need for vaccines, monoclonal antibodies, and other therapeutic solutions. Additionally, advances in various therapies are fueling the need for innovative and multifunctional excipients. <\/p>\n

 <\/p>\n

Growth of CMOs & CDMOs Segment <\/strong><\/p>\n

The CMOs (Contract Manufacturing Organizations) and CDMOs (Contract Development and Manufacturing Organizations) segment is experiencing notable growth, demonstrating the highest CAGR during the forecast period. Biopharmaceuticals, with their large molecular sizes and complex manufacturing processes, differ significantly from traditional small molecule drugs regarding behavior, production methods, and therapeutic effects. The complexities of biopharmaceutical manufacturing have led many biopharma companies to increasingly depend on CMOs and CDMOs for their specialized expertise and advanced capabilities. <\/p>\n

Outsourcing to CMOs and CDMOs has become a preferred strategy among biopharma companies, as these organizations provide the specialized knowledge and infrastructure needed for efficient production. This allows biopharma developers to focus on product commercialization and clinical development while leveraging the manufacturing expertise of CMOs and CDMOs. The growing reliance on outsourcing and the expansion of new and existing product lines—including clinical trial supply services—has significantly contributed to the steady rise in CMO and CDMO sales. <\/p>\n

 <\/p>\n

Competitive Overview <\/strong><\/p>\n

The global biopharmaceutical excipients market report features data on 36 vendors, highlighting the diverse landscape of players ranging from emerging mid-sized companies to established industry leaders. Leading companies are employing a range of strategies to boost their market share and enhance their presence. These strategies include launching new products, securing regulatory approvals, engaging in marketing and promotional efforts, investing significantly in research and development, and strengthening distribution networks. <\/p>\n

Significant players like Merck KGaA, BASF SE, Avantor, Evonik Industries, Roquette Freres, and Associated British Foods actively pursue strategic initiatives such as licensing agreements, acquisitions, and collaborations with emerging firms. These efforts enable them to rapidly enter the biopharmaceutical excipients market and gain access to commercially viable products. Companies also focus on expanding into existing and new markets to cater to a growing customer base, broadening their product portfolios, and enhancing production capabilities. <\/p>\n

Additionally, there is a push towards introducing advanced and novel excipient solutions to support pharmaceutical drug development, alongside ensuring robust distribution chains to meet evolving market demands. <\/p>\n

\u202f <\/p>\n

Buy this Research Now @ https:\/\/www.arizton.com\/market-reports\/biopharmaceutical-excipients-market<\/a> <\/strong><\/p>\n

 <\/p>\n

Key Vendors <\/strong><\/p>\n